Would you recommend enfortumab vedotin plus Pembrolizumab for localized advanced non invasive urothelial carcinoma of renal pelvis?  

What factors would you use in your consideration of EV+P in this situation? Would baseline GFR / risk of HD with nephro-ureterectomy inform this decision? What else?